SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far

被引:5
|
作者
Biondo, Carmelo [1 ]
Midiri, Angelina [1 ]
Gerace, Elisabetta [2 ]
Zummo, Sebastiana [1 ]
Mancuso, Giuseppe [1 ]
机构
[1] Univ Messina, Dept Human Pathol, I-98125 Messina, Italy
[2] ASP Azienda Sanit Prov, I-90141 Palermo, Italy
来源
LIFE-BASEL | 2022年 / 12卷 / 12期
关键词
cystic fibrosis; viral infections; COVID-19; CLINICAL CHARACTERISTICS; INNATE IMMUNITY; COVID-19; CORONAVIRUS; CHILDREN; PEOPLE; IMPACT; DISEASE;
D O I
10.3390/life12122087
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Respiratory infections are the most common and most frequent diseases, especially in children and the elderly, characterized by a clear seasonality and with an incidence that usually tends to decrease with increasing age. These infections often resolve spontaneously, usually without the need for antibiotic treatment and/or with the possible use of symptomatic treatments aimed at reducing overproduction of mucus and decreasing coughing. However, when these infections occur in patients with weakened immune systems and/or underlying health conditions, their impact can become dramatic and in some cases life threatening. The rapid worldwide spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has caused concern for everyone, becoming especially important for individuals with underlying lung diseases, such as CF patients, who have always paid close attention to implementing protective strategies to avoid infection. However, adult and pediatric CF patients contract coronavirus infection like everyone else. In addition, although numerous studies were published during the first wave of the pandemic on the risk for patients with cystic fibrosis (CF) to develop severe manifestations when infected with SARS-CoV-2, to date, a high risk has been found only for patients with poorer lung function and post-transplant status. In terms of preventive measures, vaccination remains key. The best protection for these patients is to strengthen preventive measures, such as social distancing and the use of masks. In this review, we aim to summarize and discuss recent advances in understanding the susceptibility of CF individuals to SARS-CoV-2 infection.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Cytokines and microRNAs in SARS-CoV-2: What do we know?
    Rarani, Fahimeh Zamani
    Rashidi, Bahman
    Abadi, Mohammad Hassan Jafari Najaf
    Hamblin, Michael R.
    Hashemian, Seyed Mohammad Reza
    Mirzaei, Hamed
    [J]. MOLECULAR THERAPY NUCLEIC ACIDS, 2022, 29 : 219 - 242
  • [32] Hearing Loss in SARS-CoV-2: What Do We Know?
    Saniasiaya, Jeyasakthy
    [J]. ENT-EAR NOSE & THROAT JOURNAL, 2021, 100 (2_SUPPL) : 152S - 154S
  • [33] Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?
    Lazarevic, Ivana
    Pravica, Vera
    Miljanovic, Danijela
    Cupic, Maja
    [J]. VIRUSES-BASEL, 2021, 13 (07):
  • [34] Lipschutz Ulcer and SARS-CoV-2: What We Currently Know?
    Merlino, Lucia
    Volpicelli, Agnese Immacolata
    Dominoni, Mattia
    Pasquali, Marianna Francesca
    D'Ovidio, Giulia
    Gardella, Barbara
    Senatori, Roberto
    Battino, Maurizio
    [J]. DISEASES, 2023, 11 (03)
  • [35] The SARS-CoV-2, tears, and ocular surface debate: What we know and what we need to know
    Ali, Mohammad Javed
    [J]. INDIAN JOURNAL OF OPHTHALMOLOGY, 2020, 68 (07) : 1245 - 1246
  • [36] SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t
    Paul Lingor
    Antonia F. Demleitner
    Andreas W. Wolff
    Emily Feneberg
    [J]. Journal of Neural Transmission, 2022, 129 : 1155 - 1167
  • [37] Omicron SARS-CoV-2 variant: What we know and what we don't
    Ferre, Valentine Marie
    Peiffer-Smadja, Nathan
    Visseaux, Benoit
    Descamps, Diane
    Ghosn, Jade
    Charpentier, Charlotte
    [J]. ANAESTHESIA CRITICAL CARE & PAIN MEDICINE, 2022, 41 (01)
  • [38] SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't
    Lingor, Paul
    Demleitner, Antonia F.
    Wolff, Andreas W.
    Feneberg, Emily
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2022, 129 (09) : 1155 - 1167
  • [39] Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
    Misra, Anisha
    Theel, Elitza S.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2022, 60 (06)
  • [40] Mpox infection in neonates: what we know so far?
    Kumar, Jogender
    Meena, Jitendra
    [J]. PAEDIATRICS AND INTERNATIONAL CHILD HEALTH, 2022, 42 (3-4) : 173 - 174